Translation and validation

Szczepan W. Baran, Paul C. Brown, Andreas R. Baudy, et al. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). Alternatives to Animal Experimentation. 2022;39(2):297-314. doi:10.14573/altex.2112203

Lorna Ewart, Athanasia Apostolou, Skyler A. Briggs, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine. 2022;2:154. doi:10.1038/s43856-022-00209-1

Laura Gribaldo, Adelaide Dura. EURL ECVAM Literature Review Series on Advanced Non-Animal Models for Respiratory Diseases, Breast Cancer and Neurodegenerative Disorders. Animals (Basel). 2022;12(17):2180. doi:10.3390/ani12172180

Lorenzo Del Pace, Laura Viviani, Marco Straccia. Researchers and Their Experimental Models: A Pilot Survey in the Context of the European Union Health and Life Science Research. Animals. 2022;12(20):2778. doi:10.3390/ani12202778

Tracy D. Zhang, Scott C. Kolbe, Leah C. Beauchamp, Ella K. Woodbridge, David I. Finkelstein, Emma L. Burrows. How Well Do Rodent Models of Parkinson’s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review. Biomedicines. 2022;10(12):3026. doi:10.3390/biomedicines10123026

Simon Lohse. Scientific inertia in animal-based research in biomedicine. Studies in History and Philosophy of Science Part A. 2021;89:41-51. doi:10.1016/j.shpsa.2021.06.016

Désirée H. Veening-Griffioen, Guilherme S. Ferreira, Wouter P. C. Boon, et al. Tradition, not science, is the basis of animal model selection in translational and applied research. ALTEX. 2021;38(1):49-62. doi:10.14573/altex.2003301

Biotechnology Innovation Organization, Informa Pharma Intelligence, Quantitative Life Sciences. Clinical Development Success Rates and Contributing Factors 2011-2020.; 2021:34. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf.

Hubert Dirven, Gunn E. Vist, Sricharan Bandhakavi, et al. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports. 2021;11(1):6403. doi:10.1038/s41598-021-85708-2

Michael Balls. It’s Time to Include Harm to Humans in Harm–Benefit Analysis — But How to Do It, That is the Question. Alternatives to Laboratory Animals. 2021;49(5):182-196. doi:10.1177/02611929211062223